Anand K Ganesan
Overview
Explore the profile of Anand K Ganesan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
3470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamzavi I, Ganesan A, Mahmoud B, Weiss E, Ahmed A, Robinson D, et al.
J Am Acad Dermatol
. 2024 Aug;
91(6):1104-1112.
PMID: 39182674
Background: Vitiligo lesions are often challenging to repigment with conventional medical therapies. Surgical autologous melanocyte transfer methods can be utilized for stable vitiligo but demand specialized skills and equipment. A...
2.
Ramos R, Swedlund B, Ganesan A, Morsut L, Maini P, Monuki E, et al.
Cell
. 2024 Jun;
187(13):3165-3186.
PMID: 38906093
Patterned morphologies, such as segments, spirals, stripes, and spots, frequently emerge during embryogenesis through self-organized coordination between cells. Yet, complex patterns also emerge in adults, suggesting that the capacity for...
3.
Brindani N, Vuong L, La Serra M, Salvador N, Menichetti A, Acquistapace I, et al.
J Med Chem
. 2024 Jun;
67(12):10401-10424.
PMID: 38866385
We previously reported trisubstituted pyrimidine lead compounds, namely, ARN22089 and ARN25062, which block the interaction between CDC42 with its specific downstream effector, a PAK protein. This interaction is crucial for...
4.
Interruption of the intratumor CD8 T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy
Geels S, Moshensky A, Sousa R, Murat C, Bustos M, Walker B, et al.
Cancer Cell
. 2024 Jun;
42(6):1051-1066.e7.
PMID: 38861924
PD-1 blockade unleashes potent antitumor activity in CD8 T cells but can also promote immunosuppressive T regulatory (Treg) cells, which may worsen the response to immunotherapy. Tumor-Treg inhibition is a...
5.
Xiao H, Shiu J, Chen C, Wu J, Zhou P, Telang S, et al.
bioRxiv
. 2023 Dec;
PMID: 38106189
Cutaneous melanomas are clinically and histologically heterogeneous. Most display activating mutations in or and complete loss of function of one or more tumor suppressor genes. Mouse models that replicate such...
6.
Shiu J, Lentsch G, Polleys C, Mobasher P, Ericson M, Georgakoudi I, et al.
J Invest Dermatol
. 2023 Nov;
144(4):912-915.e2.
PMID: 37952609
No abstract available.
7.
Shiu J, Lentsch G, Polleys C, Mobasher P, Ericson M, Georgakoudi I, et al.
bioRxiv
. 2023 Aug;
PMID: 37645823
Punch grafting procedures, where small pieces of normal skin are transplanted into stable vitiligo patches, results in repigmentation in only half of patients treated, yet the factors that determine whether...
8.
Wang X, Ramos R, Phan A, Yamaga K, Flesher J, Jiang S, et al.
Nature
. 2023 Jun;
618(7966):808-817.
PMID: 37344645
Niche signals maintain stem cells in a prolonged quiescence or transiently activate them for proper regeneration. Altering balanced niche signalling can lead to regenerative disorders. Melanocytic skin nevi in human...
9.
Brindani N, Vuong L, Acquistapace I, La Serra M, Ortega J, Veronesi M, et al.
J Med Chem
. 2023 Apr;
66(8):5981-6001.
PMID: 37026468
CDC42 GTPases (RHOJ, CDC42, and RHOQ) are overexpressed in multiple tumor types and activate pathways critical for tumor growth, angiogenesis, and metastasis. Recently, we reported the discovery of a novel...
10.
Ezzedine K, Peeva E, Yamaguchi Y, Cox L, Banerjee A, Han G, et al.
J Am Acad Dermatol
. 2022 Nov;
88(2):395-403.
PMID: 36370907
Background: Vitiligo is a chronic autoimmune disorder characterized by depigmented patches of the skin. Objective: To evaluate the efficacy and safety of ritlecitinib, an oral JAK3 (Janus kinase)/TEC (tyrosine kinase...